- Report
- November 2024
- 150 Pages
Global
From €5295EUR$5,950USD£4,661GBP
- Report
- October 2025
- 182 Pages
Global
From €3155EUR$3,545USD£2,777GBP
€3505EUR$3,939USD£3,085GBP
- Report
- October 2025
- 483 Pages
Global
From €5206EUR$5,850USD£4,582GBP
- Report
- September 2025
- 250 Pages
Global
From €3995EUR$4,490USD£3,517GBP
- Report
- May 2025
- 73 Pages
Global
From €3500EUR$4,213USD£3,189GBP
- Report
- October 2025
- 183 Pages
Global
From €3155EUR$3,545USD£2,777GBP
€3505EUR$3,939USD£3,085GBP
- Clinical Trials
- April 2025
- 100 Pages
Global
From €1424EUR$1,600USD£1,253GBP
€1780EUR$2,000USD£1,567GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €1780EUR$2,000USD£1,567GBP
€2225EUR$2,500USD£1,958GBP
- Report
- June 2025
- 150 Pages
India
From €5295EUR$5,950USD£4,661GBP
- Report
- July 2025
- 90 Pages
Japan
From €4939EUR$5,550USD£4,347GBP
The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more
